my report listening to the investor conference

I listened by phone and while I didn’t hear the questions very well I heard most of Matin Roger’s responses.

These are the main points I wrote down:


Pursuing fast-track of commercialisation in other jurisdictions outside US FDA.


Phase 11B will begin in the last Q this year and will probably take 18 months to complete.-sometime in 2011.Then phase 111 can begin.
He estimates that it will be around 3 years before FDA approval.

Orphan drug status application will be made quite soon and should take around 6 months to be decided. Orphan drug status is quite a separate arrangement from phase11b/111
( I am assuming by this he meant that even if it is granted phase 11B/111 will still have to be completed??)


PRR has plenty of funding and they won’t have to draw on the Fortrend loan now that the better arrangement with US based Spring Tree has been obtained. Exrtra funding can be cancelled if it is not needed.


There is no patent on dendritic cells but there are on mucin and mannon which both(?) work with the dendritic cells (in the CVAC application?). Mucin patent expires in 2014 and mannon in 2018.
PRR has patents across many different applications.

Matin Rogers sees next year as the year when things start really moving (whatever this means-maybe a partnership? Maybe the share price goes significantly north?)

PRR is the only company in the world doing late stage ovarian cancer trials.

end of summary

I also have included a point I read in the Powerpoint presentation for the investor conference:

Have already commenced selected treatment of patients in
Australia Cell Therapy -earlier this year.
(This I see as significant since if the patients being treated right now show a significantly positive response this will give the market early confidence thst the technology is an effective one)



I hope this summary is of some help.

cheers
Birdseye